China’s State Intellectual Property Office (SIPO) has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.
11 February 2015 A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.
11 February 2015 A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.
20 May 2015 Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.
11 February 2015 A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi.